

Alaska Medicaid Pharmacy and Therapeutics Committee

Meeting date Sept 21, 2012

Frontier Building, 3601 C Street; Room 890/896

**Agenda**

Call in: 1-800-315-6338. Use access code 735#.

1. **Call to Order – Chair Richard Brodsky, MD** **8:00 am**
2. **Roll Call** **8:05 am**
3. **Public Comment - Local Public / Health Practitioners** (See guidelines on page 2)

The Department's method for class review are to better utilize the time of the P&T Committee. Classes shown in **Red** are new classes or classes where \*\*new information exists and public testimony will be taken. Public testimony will be taken for classes shown in **Blue** will only if \*\*new information is received. Classes shown in **Green**, no significant changes have been noted and no public testimony will be taken.

**\*\*New information includes: new indications or drugs, new warnings, or new head to head clinical evidence.**

4. Public comment , discussion & vote on **Red Classes**

Tab 1: Re-review – Erythropoiesis Stimulating Proteins	Tab 2: Re-review – Antihyperuricemics
Tab 3: Re-review – Benign Prostatic Hyperplasia Agents	

5. Public comment, discussion & vote **Blue Classes**

Tab 4: Re-review – Anticoagulants	Tab 5: Re-review – Platelet Aggregation Inhibitors
Tab 6: Re-review – Pancreatic Enzymes	Tab 7: Re-review – Topical Psoriasis Agents

6. Discussion & vote on **Green Classes**

Tab 8: Re-review - Alzheimer's Agents	Tab 9: Re-review – Lipotropics, Other
Tab 10: Re-review – Bile Acid Salts	Tab 11: Re-review – Topical Antiviral Agents
Tab 12: Re-review – Multiple Sclerosis Agents	Tab 13: Re-review – Bone Resorption Suppression Agents
Tab 14: Re-review – Antiparkinson's Agents	Tab 15: Re-review – Pulmonary Arterial Hypertension Agents
Tab 16: Re-review – Phosphate Binders	Tab 17: Re-review – Cytokine and CAM Antagonists and Related Agents
Tab 18: Re-review – Antianginal Agent	

7. **Break as needed – 15 minutes**
8. **Review minutes from April 20, 2012 meeting**
9. **Comments from Committee Members or Chair**
10. **Adjourn**

Next Meeting Date: November 16, 2012

## **GUIDELINES FOR PROVIDING COMMENT to the ALASKA P&T COMMITTEE**

1. All interested speakers are required to provide the Committee with the name of their organization, the speaker's relationship to the organization and topic area, prior to the start of the meeting.
2. The time on the agenda for each agenda item is limited. An individual's comments to the committee are limited to a maximum of three (3) minutes in total.
3. Only one speaker "slot" will be available per drug class representing a single manufacturer or interest group. Within the allowable three (3) minute time period, multiple speakers may share this "slot".
4. NO reference or information as to pricing is allowed in any comment(s). Such information will be considered reason for immediately ending the comment opportunity.
5. It is requested that comment provided in relation to specific medications be directed toward how this product is clinically superior or the specific advantage(s) it offers, new evidence/research results or synergistic outcomes which have been demonstrated.
6. Written medical information is not accepted at the P&T meeting. This is to be submitted Magellen prior to the meeting.